PainChek (ASX:PCK): Will 2025 be the year it finally makes progress and enters the US market?

PainChek (ASX:PCK) has among the most admirable medical technologies there is, in the form of an app that can detect pain in non-verbal patients. Unfortunately, there has been pain for investors along the way. When it was announced that it was participating in a clinical trial the Morrison government was investing $5m in back in 2019, investors would have thought it’d be a tens of millions of dollar revenue business by now. This hasn’t come to pass. Adding insult to injury, companies like ResApp (ASX:RAP) were able to make progress – the latter company was bought by Pfizer.

But, if a major takeoff is going to happen at all, it could be coming soon. Specifically, FY25 could be the year the company enters the US market, a far bigger market opportunity than any of the other markets the company is in. And perhaps then, the long-held dreams of investors might finally become a reality.

PainChek’s journey to date

PainChek was founded in 2010, listed on the ASX in 2012 and was renamed PainChek to mirror its primary product in January 2018. PainChek was initially developed to help patients with dementia. Even if these patients can communicate with their carers, they have difficulty describing where the pain is and its extent. However, the app can essentially be used by anyone. Children too young to communicate linguistically, for example, have emerged as another potential class of patients. The company’s aim is not to change clinical assessments, but rather to improve them.

In early 2018, PainChek barely had a working prototype of its app, but it ha taken a long time to progress. After seeking to enter the US, it canned those plans temporarily after receiving FDA guidance that it would need a clinical trial. And so it rolled out in Australia, Europe and Asia.

In Australia, a 2019 decision by the then Morrison government to invest $5m in a clinical trial using PainChek sent shares surging. By June 2021, the company hit its milestone of 127,000 licensed Residential Aged Care beds in Australia utilising its technology. This means that it achieved 60% market penetration in Australia in just a few short years. CE Mark and TGA clearance was achieved in 2021.

As of June 30, 2024, the company had conducted over 6m pain assessments and had 90,000 licenses, equating to over 1,600 aged care facilities. However, this has not translated into the revenue that investors arguably would’ve expected off these figures – under $3m in FY24. Moreover, the Annual Recurring Revenue of existing contracts in its markets are only $4.6m according to the company’s annual report.

Now eyeing off the US

The company just might realise the anticipated revenue potential if it can enter the USA. There are 2m residential care beds there. Having previously passed on the chance to do a clinical trial there (on 105 patients), it did a trial and having completed it successfully, anticipates finalising an FDA submission in November 2024. FDA applications typically take 150 days.

With a patent lasting until 2038 and existing interest from potential distribution partners, the company anticipates it is well placed. Based on projected US pricing, there is a potential gross annual recurring revenue value of US$85m.

Conclusion

Although the company has a unique technology, whether it realises the ambitions investors have dreamed of realising for so many years, is all up to the FDA. Even though the data for PainChek looks unanimously positive, there is the risk the FDA may decline it on account of other reasons totally at their discretion. Even if it is approved, there is the risk that it may not be accepted by the market. But if the company can obtain FDA approval and PainChek is accepted by the market, the long held dreams of shareholders may finally be achieved.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips